Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial
Yoshihiko Maehara(Kyushu University), Mototsugu Shimokawa(Yamaguchi University), Ken Shirabe(Gunma University), Shunji Kohnoe(Fukuoka Dental College), Katsuhiko Uesaka(Shizuoka Cancer Center), Yoshihiro Kakeji(Kobe University), Masanori Terashima(Shizuoka Cancer Center), Yuichiro� Doki(Osaka Gakuin University), Yoshiki Sawa(Osaka Police Hospital), Mitsuru Sasako(Yodogawa Christian Hospital), Masataka Ikeda(Hyogo Medical University), Shoji Natsugoe(Kagoshima University), Eiji Oki(Kyushu University), Mitsuo Shimada(Tokushima University), Yasunori Emi(Saiseikai Fukuoka General Hospital), Shinji Üemoto(Shiga University of Medical Science), Hiroki Yamaue(Wakayama Medical University), Kazuhiro Yoshida(Kyoto Institute of Technology), Masahiro Takeuchi(The University of Tokyo), Akinobu Taketomi(Hokkaido University), Michiya Kobayashi(Kochi Medical School Hospital), Tadatoshi Takayama(Nihon University), Norihiro Kokudo(The Cancer Institute Hospital), Hideo Baba(Kumamoto University), Tomoo Kosuge(Tokyo National Hospital), Masashi Haraguchi(Nagasaki University), Masakazu Yamamoto(Tokyo Women's Medical University), Kouhei Akazawa(Niigata University Medical and Dental Hospital), Takeharu Yamanaka(National Cancer Center Hospital East)
Cited by 33
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
|The Lancet Oncology|2015|1.1k
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
|Nature Genetics|2014|780